Clot-Busting Drug After Stroke Thrombectomy Shows No Added Benefit in Brain Stem Strokes
A randomized trial finds intra-arterial alteplase after successful thrombectomy does not improve outcomes in posterior circulation stroke.
Summary
When a major blood vessel in the back of the brain is blocked, doctors can physically remove the clot using a procedure called thrombectomy. Some clinicians then inject a clot-dissolving drug called alteplase directly into the artery to clear any remaining debris. This Chinese multicenter trial tested whether that extra step actually helps. Among 246 patients with basilar artery occlusion who already had successful clot removal, adding intra-arterial alteplase did not increase the proportion who regained functional independence at 90 days (42% vs 47%). Death rates and rates of dangerous brain bleeding were also similar between groups. The findings suggest this adjunctive drug step may be unnecessary after successful thrombectomy in posterior circulation strokes.
Detailed Summary
Stroke affecting the posterior circulation — particularly blockage of the basilar artery supplying the brain stem and cerebellum — carries some of the highest mortality and disability rates of any stroke subtype. Endovascular thrombectomy (EVT), which mechanically removes the clot, has become standard care. However, even after successful recanalization, microvascular clot burden may persist, prompting some centers to infuse alteplase, a thrombolytic drug, directly into the artery immediately after the procedure. Whether this adjunctive step improves outcomes has remained uncertain.
The IAT-TOP trial was a multicenter, prospective, randomized, open-label study with blinded endpoint assessment conducted across 37 comprehensive stroke centers in China. Between September 2023 and November 2024, 246 adults with acute basilar artery occlusion who achieved successful recanalization after EVT were randomized to receive intra-arterial alteplase (0.225 mg/kg, max 22.5 mg) or no additional thrombolysis. The primary efficacy outcome was functional independence, defined as a modified Rankin Scale score of 0–2, at 90 days.
The results were clear: functional independence was achieved in 41.9% of the alteplase group versus 46.7% of controls, yielding an adjusted risk ratio of 0.93 (95% CI, 0.73–1.18; P = .55) — no statistically significant difference. Mortality at 90 days was 29.6% versus 27.0%, and symptomatic intracranial hemorrhage within 48 hours occurred in 2.4% versus 2.5% of patients, respectively. None of these differences were statistically significant.
The safety profile of adjunctive alteplase appeared acceptable, with no increase in bleeding complications. However, the lack of efficacy signal suggests the drug provides no meaningful clinical benefit in this setting.
Important caveats apply. The trial was conducted exclusively in China, limiting generalizability. The sample size of 246 patients may have been underpowered to detect modest treatment effects. Additionally, this summary is based on the abstract only, as the full text was not available, precluding assessment of subgroup analyses, imaging data, or protocol details.
Key Findings
- Functional independence at 90 days was similar: 41.9% with alteplase vs 46.7% without (P = .55).
- Mortality at 90 days did not differ significantly: 29.6% vs 27.0% between groups.
- Symptomatic intracranial hemorrhage rates were nearly identical: 2.4% vs 2.5%.
- Adjunctive intra-arterial alteplase appears safe but offers no functional benefit after successful thrombectomy.
- Findings apply specifically to posterior circulation (basilar artery) strokes, not anterior circulation.
Methodology
Multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE design) trial across 37 Chinese stroke centers. Patients with acute basilar artery occlusion achieving successful EVT recanalization were randomized 1:1 to intra-arterial alteplase or control. Primary outcome was 90-day functional independence (mRS 0–2).
Study Limitations
The trial enrolled only 246 patients, which may be underpowered to detect modest treatment effects. The study was conducted exclusively in China, limiting generalizability to other populations and healthcare systems. This summary is based on the abstract only; full methodology, subgroup analyses, and imaging data could not be reviewed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.